INTRODUCTION
The pneumococcal polysaccharide conjugated vaccine (13-valent, adsorbed; PCV13, Prevnar 13) is approved in adults C50 years for the prevention of pneumonia in the USA [1] [2] [3] . Lichenoid dermatitis describes a skin condition that is microscopically characterized by band-like lymphocytic inflammation with alteration of the epidermal basal layer. The case of a man who developed a lichenoid dermatitis at the site of immunization within 2 weeks after receiving the PCV13 vaccine is described, and cutaneous conditions occurring at vaccinations sites are reviewed. Cutaneous examination showed a 12 9 5-mm linear, focally crusted, erythematous nodule on the deltoid area of his left arm (Fig. 1) ; the location corresponded to the PCV13 injection site.
CASE REPORT
Microscopic evaluation of a 3-mm punch biopsy showed orthokeratosis, acanthosis, and a prominent granular layer. Dyskeratotic keratinocytes were present in the epidermis, and there was a vacuolar change of the basal cells at the dermoepidermal interface. In the upper dermis there was dense, band-like infiltration of lymphocytes with occasional exocytosis of the inflammatory cells into the overlying spongiotic epidermis (Fig. 2) .
Correlation of the history, clinical morphology, and pathologic changes established the diagnosis of a lichenoid dermatitis occurring at the vaccination site of the PCV13 vaccine. The residual dermatosis resolved spontaneously within 4 weeks after the biopsy, corresponding to 9 weeks after immunization. Follow-up examination showed normal-appearing skin at the vaccination site. Informed consent was obtained from the patient for being included in the study.
DISCUSSION
The 7-valent pneumococcal conjugated vaccine Cutaneous reactions at the site of PCV13 are summarized in Table 1 [1] [2] [3] [4] [13] [14] [15] [16] [17] . Local reactions such as erythema, pain and swelling at the injection site were common; they were more severe in younger aged patients than in older individuals [1] [2] [3] . The reported patient is the first individual with a lichenoid dermatitis that appeared at the vaccine injection site within 2 weeks and spontaneously resolved in 9 weeks.
Cutaneous dermatoses and malignancies have occurred at the sites of other vaccines, including Bacillus Calmette-Guerin (Table 2) [18-44], hepatitis B (Table 3 ) [28, [45] [46] [47] [48] [49] [50] [51] [52] [53] , smallpox (Table 4) [28, , tetanus (Table 5) [14, [80] [81] [82] [83] [84] [85] [86] , and others (Table 6) [36, 51, 55, 73, [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] . Granuloma annulare is one of the more common skin conditions to subsequently occur Accompanying clinical features at the injection site in some of the patients also included bluish discoloration, dermatitis, excoriations, hyperpigmentation, hypertrichosis, and scar. Contact allergy to aluminum was verified in 29 of the 34 children (85%) who were evaluated by epicutaneous testing with aluminum c Sweet's syndrome was also triggered by pneumococcal vaccination that had taken place 15 days earlier; however, the patient did not have any lesions at the injection site [17] Granuloma annulare [25, 26] Granuloma (delayed) [19] Isotopic response to patch testing [27] Keloid [7, 19, 22, 28] Lupus vulgaris (cutaneous tuberculosis) [29] [30] [31] [32] [33] Lymphadenopathy ( Pilomatricoma [35] Psoriasis [36] Sarcoidosis (juvenile) [37] Squamous cell carcinoma [33, 38] Sweet's syndrome [39, 40] Tufted angioma [41] Ulceration [18, 19, 22] Ulceration during Kawasaki disease [42, 43] Vasculitis (ulcerating) [44] at the site of an immunization [25, 26, 46, 98, 99] . The most frequently observed vaccination site-associated malignancy is basal cell carcinoma [33, 38, [55] [56] [57] 73] , followed by squamous cell carcinoma [33, 38, 54, 55, 57, 73] . However, the prevalence of melanoma [55, 57, 73] and sarcomas (dermatofibrosarcoma protuberans, fibrosarcoma, and malignant fibrous histiocytoma) [55, 57, [60] [61] [62] 72] in smallpox vaccination scars-as compared to the scars of other vaccines-is greater than expected and may be secondary to a unique characteristic of the vaccine (Table 7) Vaccine-associated adverse effects at the site of injection may, in part, be secondary to the the polysaccharides and bases it contains. However, there are no predictors as to which individuals will develop these side effects. It remains to be determined why some patients experienced inflammatory dermatoses whereas others developed neoplasms at their vaccination sites. [45] Granuloma annulare [46] Injection site reactions: edema, erythema, induration, and pain [47] Keloid [28] Mastocytoma [48] Necrobiotic granuloma [49] Nodules [50] Papulonodular lichenoid a and pseudolymphomatous reaction [47] Subcutaneous nodule (cutaneous B-cell pseudolymphoma) [51] a Generalized lichenoid reactions and lichen planus have occurred following hepatitis B vaccination; however, the initial or individual lesion was not localized to the site of vaccination [52, 53] Basal cell carcinoma [55] [56] [57] Dermatitis, chronic [54] Dermatofibroma [58, 59] Dermatofibrosarcoma protuberans [55, 57, 60, 61] Fibrosarcoma [62] Herpes simplex virus infection [63] Inflammatory reaction, localized a [64] Keloid (exaggerated scarring) [28, 55, [64] [65] [66] [67] [68] Keratoacanthoma [69] Lupus erythematosus (discoid) [70, 71] Malignant fibrohistiocytoma [55, 57, 72] Melanoma [55, 57, 73] Myxedematous infiltration, diffuse (Graves' disease) [74] Nevus sebaceous [75] Pigmentation [76, 77] Post scab lesions b [54] Progressive vaccinia c [78] Pyogenic infections [78] Robust take d [78] Scar response (normal) e [57, 78] Squamous cell carcinoma [54, 55, 57] Sweet's syndrome [79] a A localized inflammatory reaction at the vaccination site heals with a slightly depressed smooth scar that slowly fades and rarely requires treatment b The morphology of the lesion includes (in order of frequency) erythema, papule, pustule, vesicle, induration, and scab; all except induration and scab may recur in some patients after the original lesions spontaneously resolve. Lesion biopsies (in 4 patients) showed allergic contact dermatitis (2), chronic dermatitis (1), and squamous cell carcinoma (1) c Progressive vaccinia is also referred to as disseminated vaccinia, prolonged vaccinia, vaccinia gangrenosum, and vaccinia necrosum. The vaccination site does not heal; there is painless progressive necrosis that develops into an ulcerative lesion. Additional lesions may or may not appear at distant sites, such as skin, bone, and viscera d Robust take is a non-progressive cutaneous reaction at the vaccination site of [7.5 cm with swelling, warmth, and joint pain; the symptoms peak at 8-10 days post vaccination, and there is improvement within 24-72 h e The normal scar response at the site of vaccination is the following sequence: papule at day 4 post vaccination, pustule at day 7-14, and scab at day 21 Angiolymphoid hyperplasia with eosinophils [80] Indurated erythematous plaque (cutaneous B-cell pseudolymphoma) [51] Granuloma annulare [81] Tetanus and diphtheria vaccine Granuloma annulare [26] Tetanus, diphtheria, and pertussis vaccine Abscess (Mycobacterium tuberculosis) [82] Deep reactive nodular infiltrates of mixed inflammation [83] Necrotizing granuloma [83] Tetanus, diphtheria, pertussis, and polio vaccine [51] Influenza vaccine Psoriasis [36] Sweet's syndrome [87] [88] [89] Leishmaniasis vaccine Dermatofibrosarcoma protuberans [90] Varicella-zoster virus vaccine Burning [91] Erythema [91] Pruritus [91] Subcutaneous nodule (pseudolymphoma) [92] Zosteriform eruption [93] Vaccine not specified Basal cell carcinoma [55, 73] Dermatofibrosarcoma protuberans a [55, 94, 95] Lentigo maligna [96] Lichen sclerosus et atrophicus [97] Melanoma [55] Squamous cell carcinoma [55, 73] a Includes pigmented dermatofibrosarcoma also referred to as Bednar tumor [55, 94] 
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